Published 9th May 2016

TopiVert to present data from Phase I clinical study

Portfolio company TopiVert, a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it will present posters on the Phase I study data results and pre-clinical pharmacology for TOP1288, its lead compound for the treatment of ulcerative colitis (UC) at the Digestive Disease Week (DDW) 2016 in San Diego, California, from 21-24 May.

For more details, read the full release here